A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study To Evaluate The Efficacy and Safety Of CC-90001 In Subjects With Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Latest Information Update: 08 Jun 2023
At a glance
- Drugs BMS 986360 (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Celgene Corporation
Most Recent Events
- 23 Feb 2022 This trial has been completed in Poland (global end date of the trial: 28-09-2021) according to European Clinical Trials Database record.
- 19 Oct 2021 Status changed from active, no longer recruiting to discontinued.
- 31 Aug 2021 Planned End Date changed from 4 Oct 2024 to 8 Oct 2021.